Loading... Please wait...
Sort by:
Next »
  • Trends in Digital Pharma Marketing (2020)
    Learn More Trends in Digital Pharma Marketing (2020)
    How has COVID-19 impacted pharma digital marketing activity—now and for the future? The effects of coronavirus on pharma marketing budgets, priorities and actions cannot be ignored. During the pandemic, pharma...
  • MSL-KOL Engagement [2020]
    Learn More MSL-KOL Engagement [2020]
    Maintaining and growing KOL relationships in pandemic lockdown At a stroke, the COVID-19 pandemic shut down MSL's principal KOL engagement channels. With face-to-face interactions on hold, MSLs have turned to...
  • The Rise of ICER – The Payer Perspective
    Learn More The Rise of ICER – The Payer Perspective
    Payers reveal where ICER is really impacting pharma/payer relations How is the Institute for Clinical and Economic Review (ICER) influencing payer behavior? ICER's evidence and price benchmarking data are valued by...
  • The State of Pharma Digital Transformation 2020
    Learn More The State of Pharma Digital Transformation 2020
    How far has pharma come, and what does it still need to do, to realize the full benefits of digital technology across its business? The COVID-19 pandemic may have spurred rapid expansion in the use of digital tools but...
  • Telemedicine’s Move into the Mainstream
    Learn More Telemedicine’s Move into the Mainstream
    COVID-19 accelerated uptake of telemedicine is rapidly transforming healthcare delivery Telemedicine is one major success story of the pandemic. Barriers previously hindering widespread adoption of telehealth practices...
  • Smart Pharma Sales: How Digital is Reinventing the Process
    Learn More Smart Pharma Sales: How Digital is Reinventing the Process
    Post COVID-19, pharma's opportunity is to build on the impact of digital technology to revolutionize its sales practice and engagement strategies The COVID-19 pandemic has radically reshaped how pharma does sales and...
  • Engaging with ICER: Lessons and insights for pharma
    Learn More Engaging with ICER: Lessons and insights for pharma
    ICER is here to stay so how best can industry engage for its benefit? The Institute for Clinical and Economic Review (ICER) is gaining a growing reputation with US payers. While ICER's drug assessments are advisory, and...
  • Digital Health and the Management of Chronic Disease
    Learn More Digital Health and the Management of Chronic Disease
    Essential strategies for developing next phase digital health solutions The COVID-19 pandemic has accelerated and elevated the role of digital health and could serve as a turning point for digital platforms to become...
  • COVID-19 Implications for pharma: US payer insights
    Learn More COVID-19 Implications for pharma: US payer insights
    What are the implications for pharma as COVID-19 forces fundamental change in US payer practice and policy? The COVID-19 pandemic has created a unique set of challenges for US payers. In the short-term emergency...
  • Measuring Digital Success in Pharma: Essential KPIs
    Learn More Measuring Digital Success in Pharma: Essential KPIs
    Which KPI's should pharma be using to assess the success of its digital technology investments? The Covid-19 pandemic is fundamentally changing working practice and driving immediate expansion of digital solutions. But...
  • Biosimilars: US Payer Insights 2020
    Learn More Biosimilars: US Payer Insights 2020
    What do payers see as unlocking the sluggish US biosimilar market? Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector...
  • Digital Biomarkers: Pharma’s clinical development future?
    Learn More Digital Biomarkers: Pharma’s clinical development future?
    Assessing digital biomarker applications that could radically impact pharma's clinical research practice By precisely and continuously measuring disease symptoms, digital biomarkers can allow pharma to establish valid...
  • Drivers of Non-medical Rx Switching
    Learn More Drivers of Non-medical Rx Switching
    The strategies that are promoting wider use of biosimilars Payers are highly motivated to realise the cost savings of biosimilars, but what strategies are they using to reassure and encourage physicians and patients?...
  • The MSL Technology Survey (2020)
    Learn More The MSL Technology Survey (2020)
    With physical distancing currently the norm, MSLs must radically change their working practice to effectively engage with KOLs Face-to-face meetings are the preferred choice of MSLs when sharing key scientific...
  • Trends in Digital Physician Engagement
    Learn More Trends in Digital Physician Engagement
    Next level opportunities for developing physician relationships across pharma's business Digital technology has transformed pharma's communications with often difficult to engage physicians. But merely having a suite of...
  • Trends in Digital Patient Engagement
    Learn More Trends in Digital Patient Engagement
    Embedding digital patient engagement throughout the patient journey Pharma companies have made good progress with digital delivery within innovative patient support programs—but there is still significant scope to...
Next »

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved